Instil Bio Pulls Plug On Lead Drug Development

Instil Bio, Inc. (NASDAQ:TIL) stock is trading lower on Tuesday. Axion Bio Inc., a wholly-owned subsidiary of Instil, decided to discontinue clinical development of AXN-2510.AXN-2510, Instil’s lead asset, is a PD-L1xVEGF bispecific antibody in development for multiple solid tumors.Axion and ImmuneOnco Biopharmaceuticals have agreed to terminate the license and collaboration agreement for AXN-2510 and AXN-27M.Also Read: Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock SoarsAll rights previously li ...